Skip to content

Ketamine research published in 2026

Page 16 of 35: studies 301 to 320 of 700, newest first. Back to the ketamine overview

Studies

Effect of esketamine-assisted regional block on post-traumatic stress disorder after radical lung cancer surgery: A retrospective clinical study

World Journal of Psychiatry June 19, 2026 Yan-Lin Chen, Tengchen Feng, Xiao-Min Zhang et al.

BACKGROUND Post-traumatic stress disorder (PTSD) is a common psychological complication after radical lung cancer surgery and has a significant impact on postoperative recovery and quality of life. Esketamine, a new anesthetic agent, may be protective against postoperative PTSD through modulation of neurotransmitter systems and anti-inflammatory actions. AIM To explore the underlying mechanisms...

Ketamine for the Treatment of Obsessive-Compulsive Disorder (OCD): A Systematic Review on Efficacy and Tolerability.

Clinical Neuropharmacology June 19, 2026 Isabela Heroiu, Gia Han Le, Maria‐christina Sioufi et al.

This systematic review aims to assess the efficacy and tolerability of ketamine in the treatment of obsessive-compulsive disorder. Obsessive-compulsive disorder is a chronic and severe disorder characterized by intrusive thoughts and repetitive behaviours that can cause significant distress. Notwithstanding current treatments and interventions for obsessive-compulsive disorder, some individuals...

Ketamine-assisted psychotherapy for posttraumatic stress disorder: a systematic review and individual participant data meta-analysis of predictors of treatment effects.

Psychotherapy and Psychosomatics June 19, 2026 Judith Rohde, Tyler M Moore, Kathryn Walker et al.

Ketamine combined with psychotherapy has shown promise in treating posttraumatic stress disorder (PTSD), but predictors of clinical benefit remain unclear. In this systematic review and individual participant data meta-analysis (IPDMA), we examined patient- and treatment-level predictors of PTSD symptom change after combined treatment. Eligible studies combined ketamine with psychotherapy in...

At-Home Telehealth-Supported Subcutaneous Ketamine Therapy in Adults With Moderate to Severe Depression, Anxiety, or PTSD: A Real-World Observational Study of Safety, Feasibility, and Clinical Outcomes in a Large, Heterogeneous Cohort in the United States.

Journal of Medical Internet Research June 17, 2026 Acacia C Parks, Amanda L Woodward, Robert D Henry et al.

Background: Depression, anxiety,, and PTSD are leading global causes of disability. Standard interventions utilize slow mechanisms of action, high attrition, and significant accessibility barriers. While intravenous (IV) and intranasal ketamine are rapid-acting alternatives, high cost and intensive logistical requirements limit adoption. Sublingual (SL) at-home ketamine addresses some gaps but...

Prophylactic efficacy of cannabidiol and sodium nitroprusside in a ketamine model of schizophrenia: sex-dependent effects on positive-like and cognitive impairments

Brazilian Journal of Psychiatry June 16, 2026 Daniel B.a. Prado, Matheus T. Rossignoli, Rafael N. Ruggiero et al.

Objective: Current treatments for schizophrenia (SZ) are often not effective for all symptoms, with sex-dependent effects poorly understood. Cannabidiol (CBD) and sodium nitroprusside (SNP) have emerged as potential prophylactic options. We evaluated their efficacy in preventing positive, negative, and cognitive deficits in a ketamine (KET) rodent model of SZ in both sexes. Methods: Wistar rats...

Burnout Symptom Outcomes During At-Home Ketamine-Assisted Therapy: A Real-World Retrospective Analysis of 395 Adults

Research Square June 16, 2026 Jack Swain, Davis Carter, Leonardo Vando et al. preprint

Abstract Background Occupational burnout, recognized in ICD-11 as an occupational phenomenon, is a syndrome of chronic workplace stress comprising emotional exhaustion, cynicism (the analogue of the depersonalization dimension on the MBI-Human Services Survey form), and reduced professional efficacy on the Maslach Burnout Inventory-General Survey (MBI-GS). Burnout is common among US working...

Increased brain VDAC1 protein levels correlate with behavioural performance in a ketamine murine model of schizophrenia and are attenuated by the mGluR2 modulator JNJ-46356479.

Schizophrenia Research June 16, 2026 David Olivares-Berjaga, Natàlia Rodríguez, Albert Martínez-pinteño et al.

Schizophrenia (SZ) is a neurodevelopmental disorder involving excitatory/inhibitory imbalance and apoptotic dysregulation. VDAC1, a voltage-dependent anion channel protein located in the mitochondrial outer membrane, plays a pivotal role in mitochondria-mediated apoptosis. However, its involvement in SZ remains underexplored. This study aimed to investigate VDAC1 protein levels in the...

Modulation of early non-rapid eye movement slow wave activity by ketamine in treatment-resistant depression.

Neuropsychopharmacology June 16, 2026 Nadia S. Hejazi, Mina Kheirkhah, Brady A. Riedner et al.

Slow-wave activity (SWA), a key indicator of sleep homeostasis, is often diminished in individuals with treatment-resistant depression (TRD). Ketamine, a rapid-acting antidepressant, increases SWA during the first period of non-rapid eye movement (NREM1) sleep. However, research into how ketamine affects sleep and its connection to treatment outcomes in TRD has been limited by small sample...

Intranasal esketamine in treatment-resistant depression with and without comorbid borderline personality disorder: A multicenter real-world longitudinal study.

Psychiatry Research June 16, 2026 Filippo Mazzoni, Fabiola Raffone, Arianna De Ciechi et al.

Borderline personality disorder (BPD) often occurs alongside treatment-resistant depression (TRD), but the impact of BPD on real-world outcomes with intranasal esketamine is unclear. Consecutive TRD outpatients initiating intranasal esketamine treatment at four Italian centres between 1 September 2024 and 30 September 2025 were enrolled in the study (n = 90): 45 with comorbid BPD and 45 without...

KETAMINE IN THE TREATMENT OF DEPRESSION - A REVIEW ARTICLE

International Journal of Innovative Technologies in Social Science June 15, 2026 Olga Szeidl, Joanna Mikołajczyk, Artur Hawajski et al.

Background: Depression is a multifactorial disorder involving neurotransmitter dysregulation, HPA axis hyperactivity, neuroinflammation, and impaired neuroplasticity. While combination psychotherapy and pharmacotherapy remains first-line, ~30% of patients develop TRD. In the last few years ketamine has emerged as a rapid-acting therapeutic option for treatment-resistant cases. Aim: To review...

Acute Effects of Esketamine on the EEG Power Spectrum and Signal Complexity in Prolonged Disorders of Consciousness: A Prospective Exploratory Cohort Study.

Journal of neurosurgical anesthesiology June 15, 2026 Yi Liang, Wanning Yang, Xinxin Wang et al.

Effective treatments for prolonged disorders of consciousness (pDoC) remain limited. Grounded in the entropic brain hypothesis-that psychedelic agents facilitate consciousness recovery by increasing brain complexity-this study investigated esketamine, a nonclassical psychedelic drug, and its effects on electroencephalographic (EEG) neurophysiological metrics in pDoC patients. In this...

DOI: 10.1097/ana.0000000000001124 (opens in new tab) Full text (opens in new tab) Esketamine Lempel-ziv complexity Electroencephalography Power spectral density

Development and validation of a short-form (6-item) version of the clinician-administered dissociative states scale (CADSS-SF).

European Journal of Psychotraumatology June 15, 2026 V Ursule Taujanskaite, Sunjeev K. Kamboj

Background: State dissociation is commonly assessed using the Clinician Administered Dissociative States Scale (CADSS; 19-items). A briefer CADSS would have many advantages, enabling assessment of transient dissociative states and allowing repeated assessment within short intervals while minimizing participant burden. This is especially relevant in studies of dissociative drugs which cause...

THE PSYCHEDELIC AND KETAMINE RENAISSANCE IN THE FACE OF THE CRISIS IN MODERN PSYCHIATRY

International Journal of Innovative Technologies in Social Science June 15, 2026 Julia Osipowska, Marlena Kwolek, Alicja Judzińska et al.

Introduction: Contemporary psychiatry is grappling with a profound stagnation in innovation. It is primarily relying on the chronic management of symptoms through traditional daily-dose pharmacotherapy. The emergence of psychedelics and ketamine marks a significant departure from this model. It is offering rapid-acting, interventional alternatives that target the underlying neurobiological...

DOI: 10.31435/ijitss.2(50).2026.5605 (opens in new tab) Multidisciplinary approach Bioethics Face sociological concept Licensure +4

Acute pretrauma ethanol exacerbates PTSD-like phenotype in rats and is reversed by early intranasal ketamine

Scientific Reports June 14, 2026 Bar Eilat Yogev, Gal Levi, Noa Efroni et al.

Alcohol consumption before trauma is a prevalent but understudied risk factor for posttraumatic stress disorder (PTSD). This study investigated whether acute ethanol exposure prior to trauma modulates PTSD-like symptom development in rats, identified hippocampal mechanisms involved, and tested an early post-trauma intervention. Adult male Sprague-Dawley rats received ethanol (1.6 g/kg, 40% v/v,...

Ketamine and Evolving Neuroplasticity.

Clinical drug investigation June 13, 2026 Angel Prabakar

Ketamine has revolutionized the treatment of mood disorders by offering rapid antidepressant effects, particularly in individuals with treatment-resistant depression. Unlike traditional monoaminergic antidepressants, ketamine acts primarily through antagonism of the N-methyl-D-aspartate (NMDA) receptor, initiating a cascade of glutamatergic signaling that promotes synaptic plasticity,...

Esketamine for negative emotions and cognitive function in general anesthesia: a systematic review and meta-analysis

Frontiers in Medicine June 12, 2026 Xiaofan Yang, Jing Qin, Wenqing Xu

Introduction This study aims to systematically evaluate, through a systematic review and meta-analysis, the effect of esketamine on postoperative negative emotions (anxiety and depression) and cognitive function in patients undergoing general anesthesia. Methods Following PRISMA guidelines, we systematically searched PubMed, Web of Science, Embase, Cochrane Library, and CNKI to identify studies...

Effect of postoperative esketamine on depression after pancreatoduodenectomy: a randomized controlled trial.

Perioperative medicine (London, England) June 12, 2026 Bowen Zhang, Zhun Wang, Kaili Yu et al.

Pancreaticoduodenectomy (PD) can lead to major trauma in terms of patients' mental health, including severe postoperative depression. This study aimed to investigate the effects of supplementing patient-controlled analgesia with low-dose esketamine on postoperative depression among patients undergoing PD. Eighty patients who were scheduled for PD were randomly assigned to either the control or...

DOI: 10.1186/s13741-026-00711-3 (opens in new tab) Full text (opens in new tab) Esketamine Analgesia Pancreaticoduodenectomy Postoperative depression

Esketamine linked to remission across six TRD clinical trials

Mental Health Weekly June 12, 2026 Valerie A. Canady

For many patients with major depressive disorder, reaching remission — not just partial response — can significantly alter the course of illness, lowering the risk of relapse and improving day‐to‐day functioning. Yet that goal remains elusive for those with treatment‐resistant depression (TRD), where repeated medication failures, comorbid conditions, and lingering symptoms complicate care. Data...

Intranasal Esketamine Versus Other Pharmacological Strategies in Treatment-Resistant Depression with High Suicide Risk: A Six-Month Naturalistic Study.

Clinics and practice June 12, 2026 Ana María De Granda-Beltrán, Alejandro Porras-Segovia, Daniel Núñez-arias et al.

Background: Treatment-resistant depression (TRD) poses a major clinical challenge, particularly when accompanied by suicidal behavior. Intranasal esketamine has demonstrated rapid antidepressant effects in TRD, but real-world comparative evidence remains limited. Methods: We conducted a six-month naturalistic prospective cohort study in two Spanish mental health centers, including 62 TRD...